Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10371088" target="_blank" >RIV/00216208:11110/17:10371088 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/17:10371088

Výsledek na webu

<a href="http://dx.doi.org/10.1038/bmt.2016.213" target="_blank" >http://dx.doi.org/10.1038/bmt.2016.213</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bmt.2016.213" target="_blank" >10.1038/bmt.2016.213</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Popis výsledku v původním jazyce

In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and &gt;2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed &lt;6 months (5.7 months) compared with those relapsing &gt;= 12 months after ASCT (12.6 months, P = 0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P&lt;0.0001), 10.0 (P = 0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and &gt;2: 5.3 months (P = 0.0007). In multivariate analysis, tIPI &gt;2, achievement of response and remission lasting &lt;6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.

Název v anglickém jazyce

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Popis výsledku anglicky

In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and &gt;2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed &lt;6 months (5.7 months) compared with those relapsing &gt;= 12 months after ASCT (12.6 months, P = 0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P&lt;0.0001), 10.0 (P = 0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and &gt;2: 5.3 months (P = 0.0007). In multivariate analysis, tIPI &gt;2, achievement of response and remission lasting &lt;6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bone Marrow Transplantation

ISSN

0268-3369

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

216-221

Kód UT WoS článku

000394134300009

EID výsledku v databázi Scopus

2-s2.0-84988369353